 With this, we begin the preceding of this session, Honorable Prime Minister of India Shri Narendra Modiji, Dr. Mansukh Mania, Union Minister for Health, Family Welfare, Chemicals and Fertilizer, esteemed industry leaders and patrons across the globe, ladies and gentlemen. I am privileged to extend a very warm welcome to all dignitaries at the first Global Innovation Summit, a very important day for the Indian pharmaceutical industry, academia, investors, innovators and researchers. We are truly honored and privileged to have with us today, Shri Narendra Modiji, Honorable Prime Minister of India, a constant source of inspiration. Thank you, sir, for being with us today. We have gathered here today to showcase the strength of India's pharmaceutical sector as we strive to also become a leader in research, development and innovation. Once again, I welcome you all to witness and participate in India's journey from making India towards discovery in India. Without further ado, may I now invite Mr. Sami Mehta, President Indian Pharmaceutical Alliance for his introductory remarks. Mr. Mehta, please. Honorable Prime Minister, Shri Narendra Modiji, Dr. Mansook Mandavya, Honorable Minister for Health and Family Welfare and Chemicals and Fertilizers, Mr. Pankaj Patil, Chairman Kedila Healthcare and also the Chairman of Innovation Committee of IPA, which has been responsible for organizing today's event. All key Indian and global stakeholders from the government, industry, academia, investors and researchers. A very good evening and a warm welcome to the first Global Innovation Summit. Today marks an important event for the Indian Pharma sector as we inaugurate the first Global Innovation Summit. This summit will serve as a flagship event to build the sector's position in R&D and innovation as we embark on the journey from making India to discovering India. This is built on the theme of Atma Nirbh Bharat as envisioned by our respected Prime Minister, Shri Narendra Modiji. The Global Innovation Summit has an apt theme of discovering India, accelerating the innovation journey of the Indian life sciences industry. The summit aims to bring together key Indian and international stakeholders to discuss and strategize priorities to foster a thriving innovation ecosystem in the pharma industry in India. We have all industry associations coming together for this summit and over 2,500 participants from India and many parts of the world including US, Europe, Japan and elsewhere have resisted today indicating the right to take the innovation agenda forward. This summit is the first of its kind being organized in our country. The key objectives of the summit are to take stock and discuss recommendations to improve innovation landscape in India, share learnings and emerging trends in the global innovation space, provide platform for entrepreneurs and researchers to showcase their ideas to support discover India and enhance access. Today it is an honor for us to have Honorable Prime Minister Shri Narendra Modiji to inaugurate the summit and share his vision for the industry. The inauguration session will feature a special address from our respected Minister for Health and Family Welfare and Chemical and Fertilizers, Dr. Mansukh Mandaviya. The summit will have 12 sessions and over 40 national and international speakers deliberating on the important building blocks of a strong R&D and innovation ecosystem. These building blocks are creating an enabling regulatory environment, improving access to funding for innovation and R&D and promoting industry academia collaboration and infrastructure development. These discussions will take place in the form of engaging panel discussions, covering the diverse viewpoints from the government, academia, industry and investors perspective. In addition to the panel discussions, we will have addresses from senior government leaders covering the policy aspect of building India's innovation ecosystem. This summit will also explore best practices and the experiences of prominent scientists and innovators from across the world. This summit will certainly help advance the focus on R&D and innovation in India. I am sure that each one of us present here will have a great meaningful learning experience and help us move forward in the journey of innovation. Thank you very much and once again a very warm welcome to all of you. Thank you Mr. Mehta. Moving to our next speaker, I will now request Mr. Pankaj Patel, Chair of the Chadila Health Care to please deliver his remarks. Mr. Patel, over to you. Thank you very much, respected Prime Minister of India, Sri Narandrabai Motiji, Dr. Mansukh Madhavya, Honourable Minister for Health, Family Welfare, Chemical and Fertilizer, my colleagues from the industry, the global leaders and stakeholders, the government officials, industry academia, party participants, investors, researchers from all over the world. Welcome and it is indeed a pleasure to see you all in this conference. It is honour to have among us our Honourable Prime Minister, Narinder Motiji, whose leadership vision has given the inspiration for all of us in creating an Atma Nibbar Bharat in healthcare. It also looked forward to a special from him today to further booster our morale and our capabilities going forward. The Indian pharmaceutical industry has been at the forefront of the service of the nation. For 120 years, it has been making a difference in the people's lives across the world by providing access to therapies and reducing the disease burden across the world. Rightly called the pharmacy of the world, India contributes about 20% share of the global supply of medicines by volume and supplies around 60% of demand of vaccines globally. The Indian pharmaceutical industry is a $45 billion industry in size and ranks third worldwide in production of volume and 13th in value. India has played a vital role in supply of high quality medicines for several diseases like chronic myeloid leukemia, hepatitis, HIV, AIDS, to name a few. India today is polio-free because of the strong collaboration among vaccine manufacturers, healthcare providers, government and development organisations. Global unmetals like Nefeld, Nash, which has no cure anywhere in the world can be now treated today with a product of Indian innovation, saroglitazar. India's researchers have individually developed vaccines for COVID-19 in record time like Bharat Biotex co-vaccine and also the world's first DNA vaccines, ICODE. During the pandemic, which witnessed one of the toughest healthcare challenges of all the times, the Indian pharmaceutical industry rose to the challenge and effectively managed all critical supplies of diagnostics, vaccine, therapeutics to people of India. People in India and across the world continue to depend on Indian vaccines and pharmaceutical manufacturers to get their supply of medication. As per data, India exported 6.63 crore doses of COVID vaccines to more than 95 countries in since May 2021. India thus is all set to play an even bigger role in the world drug security and most favoured pharmaceutical market in the world. Anir Barba took a whole new meaning with India underlining the importance of self-liar reliance and agility on certain times. IPA has always played an important role in addressing the needs of future development of Indian pharmaceutical industry and the country. After focusing a lot on quality excellence, IPA is now converging the stakeholder for a meaningful dialogue on innovation as well. We thank the government for all the support led by our Honourable Prime Minister, Sri Marendra Modi. Recently, Government India has relieved draft R&D policy, catalyzed research and development and innovation in pharma and medtech sector in India on 25th October 2021. The objective is to send in the innovation ecosystem for pharmaceutical sector in India and encourage research and development activity. India, despite of its strong position in generics, has yet to demonstrate sustained high capability in pharmaceutical drug delivery and bio-pharmaceutical new drug development. We account for significant share in the generic market, however, we have to go long way in innovative space which accounts for 65% of the global pharmaceutical market. Furthermore, building an innovative ecosystem will be a game changer. In India, the Indian pharmaceutical industry is poised to take a big lift forward in this decade. The vision of industry is to move to $130 billion size by 2030. Building further on the mission of self-reliant Atman Ibarath, we need to see how innovation can be the new pillars of success for growth by 2030, only be possible moving as we are moving ahead in a value chain. This summit is a path-breaking one and as we are looking for a different dimensions and approaches to create an innovation ecosystem in India, it will make a huge contribution to the all proceedings. On the make in India to discover in India, we will explore how industry can bring innovation at the center stage. To make it this happen, we need to understand how the foundation of a strong innovative culture can be inbuilt at every step of innovation value change. This will include infrastructure, building capabilities, retaining talent, promoting academia industry collaboration and so on. Understanding the best approaches that have worked globally will also need to see how it can take root in India and be sustainable in our context. We are poised at a new beginning which brings together different stakeholders on one single platform of making R&D and innovation in India a force to reckon with. I am sure that all of us together will have to co-create a new horizon where innovation strengthens the Atmanir Barbarat. We are encouraged by the support and guidance provided by our honorable Prime Minister for this event and we are thankful for him to be with us today to motivate us to more. Thank you very much. Jai Hind. Namaskar. Thank you, Mr. Patel. Next, may I please request Dr. Mansukh Manviya, Union Minister for Health and Family Welfare and Chemicals and Fertilizers to share his thoughts with us. Sir, please. Respected honorable Prime Minister and all dignitaries and participants, I am happy to join the inaugural session of the first Global Innovation Summit 2021, organized by Indian Pharmaceutical Alliance focusing on innovation in pharmaceutical sector. Today is also an occasion when we may be celebrate the strength of India in terms of our youth innovation and making India. I would like to remember few words of honorable Prime Minister. He has rightly mentioned in a young entrepreneurship summit in 2017 that where convention fails, innovation starts under the able leadership of honorable Prime Minister, Shri Narendra Modi ji in his focusing to complete cycle of pharmaceuticals. Starting with innovation, R&D to finished products. Honorable Prime Minister has given the vision of Atma-Lirbar Bharat that is self-reliant India. In recent times, India has announced different PLI schemes for pharmaceuticals and medical equipment. Beach will not only help to reduce import burden but also help us to become secure in critical drugs. I would like to thank and appreciate the contribution of our Indian pharma industries. During these challenging times of COVID-19 pandemic, Indian pharma industries thrived in this challenging time and proved itself as pharma, pharmacy for the whole world. In the initial period of pandemic, India provided critical drugs to over 150 countries in the time of need and still continuing the supply of all essential drugs. Our research policy on health is also in advanced stage which will provide right platform for innovation to our scholars. I would like to mention here that India has administered around 1.15 billion COVID vaccine doses which is highest in the world. These vaccines are manufactured in India as well as it is also researched and developed in India. This is the first time when India started vaccination for any disease with other developed countries. This reflects our brand power, skill of scientists, manufacturing capacity and most importantly the able leadership which provided all necessary funds, supports and guidance to make this happen. Our minister guide us on all policy issues of pharmaceuticals and health sector to frame it with consideration of not only India but also for the world. India has all necessary infrastructures and ecosystem to become healer of the world. This pandemic has given the world so many lessons and the importance of drug security is one of them. When any countries invest in India, their drug security is as good as when they create a manufacturing facility in their country. I urge upon the world to join the journey of discovering India, making India and investing in India. I am very much confident that India will achieve the very ambitious target of 130 US billion dollar pharma industries by 2030. Honourable Prime Minister has also given carry-on call of vaccine for all to the world and committed contribution of 5 billion doses by 2022. Our pharma industries is aggressively working towards achieving the target ahead of time. I extend my best wishes to Indian Pharmaceutical Alliance and all participants for the grand success of Global Innovation Summit. Thank you. Namaste. Thank you so much, sir. With this, ladies and gentlemen. My colleague in the cabinet, Sriman Sukhbhai, President of the Indian Pharmaceutical Alliance, Srisamir Mehta, Chairman of Kediva Healthcare Limited, Sri Pankaj Patel, distinguished participants. Namaste. At the outset, I congratulate the Indian Pharmaceutical Association for organizing this Global Innovation Summit. The COVID-19 pandemic had brought the importance of the health care sector into sharp focus whether it is lifestyle or medicines, medical technology or vaccines. Every aspect of health care has received global attention over the last two years. In this context, the Indian pharmaceutical industry has also reasoned to the challenge. The global trust earned by the Indian health care sector had led to India being called the pharmacy of the world in recent times. Employing nearly 3 million people and generating a trade surplus of about 13 billion dollars, the Indian pharma industry had been a key driver of her economic growth. The combination of high quality and quantity at affordable prices has generated immense interest in the Indian pharma sector around the world. Since 2014, the Indian healthcare sector has attracted over 12 billion dollars in foreign direct investment. And there is still potential for much more. Friends, our definition of wellness is not limited by physical boundaries. We believe in the well-being of the entire humankind. And we have shown this period to the whole world during the COVID-19 global pandemic. We exported life-saving medicines and medical equipments to over 150 countries during the initial phase of the pandemic. We have also exported more than 65 million doses of COVID vaccines to nearly 100 countries this year. Over the coming months, as we ramp up our vaccine production capacities, we will do much more. Friends, the importance of innovation had been reinforced in the COVID-19 era in all walks of life. The disruption forced us to reimagine for our lifestyles the way we think and we work. In the context of the Indian pharma sector too, the speed, scale, and willingness to innovate had been truly impressive. For example, it is this period of innovation that led to India becoming a major producer and exporter of PPEs. And it is the same spirit of innovation that led to India being at the forefront of innovating, producing, administering, and exporting COVID-19 vaccines. Friends, the same spirit of innovation is reflected in the staff being taken by the government to encourage growth in the pharma sector. Last month, the government has released a draft document outlining the policy catalyzed research and development and innovation in the pharma, meditech, sector in India. This policy reflects India's commitment to encourage R&D in pharmaceutical and medical devices. Our vision is to create an ecosystem for innovation that will make India leader in a drug discovery and innovation medical devices. Our policy interventions are being made based on wide consultation with all stakeholders. We are sensitive to the industry demands on regulatory framework and are actively working in this direction. The industry has got a major boost through the production linked incentive schemes worth over 30,000 crore rupees for the pharmaceutical and medical devices. Friends, the support of industry, the academic world and specially our talented youth is important. That is why we are encouraging collaboration between academia and industry. India has a large pool of scientists and technologies with the potential to take the industry to greater heights. This strength needs to be harnessed to discover and make in India. Friends, I also wish to highlight two areas which I want you to explore carefully. The first one relates to raw material requirements. While we have been fighting COVID-19, we found that this was one issue that needs much more attention. Today, when 1.3 billion people of India have taken it upon themselves to make India Ahmadirva. We must think about ramping up domestic manufacturing of key ingredients for vaccine and medicines. This is one frontier that India has to conquer. I am sure that investors and innovators are keen to work together to overcome these challenges as well. The second area relates to India's traditional medicines. There is now significant and growing demand of these products in the international markets. This can be seen through the sharp rise in export of these products in recent years. In 2021 alone, India exported harpal medicines worth over 1.5 billion dollars. The WHO is also working to set up its global center for traditional medicines in India. Can we think of more ways to popularize our traditional medicines in the line with global requirements? Scientific standards and based manufacturing practices. Friends, I invite you all to ideate in India, innovate in India, make in India and make for the world. Discover your true strengths and serve the world. We have the talent, resources and ecosystem required for innovation and enterprise. Our rapid strides, our spirit of innovation and the scale of our achievements in the pharma sector have been noticed by the world. This is the best time to move forward and scale new heights. I assure global and domestic industry leaders and stakeholders that India is committed to enhance the ecosystem for innovation. May this summit serve as a flagship event to strengthen the Indian pharmaceutical industry position in R&D and innovation. I once again congratulate the organizers and wish the deliberations during this two-day summit will be fruitful. Thank you. Thank you very much. Thank you, sir, for your highly inspiring words. We are truly honored by your presence and we once again...